Mode
Text Size
Log in / Sign up

Network meta-analysis of pediatric atopic dermatitis treatments shows dupilumab and pimecrolimus efficacy

Network meta-analysis of pediatric atopic dermatitis treatments shows dupilumab and pimecrolimus…
Photo by Laura Borders / Unsplash
Key Takeaway
Consider dupilumab or pimecrolimus for pediatric atopic dermatitis based on network meta-analysis evidence.

This network meta-analysis evaluated multiple interventions for pediatric atopic dermatitis, including dupilumab, pimecrolimus, melatonin, probiotics, tralokinumab, nemolizumab, and vitamin D. The analysis included 3961 children and assessed outcomes such as SCORAD and EASI scores. The authors used the CINeMA tool to grade certainty of evidence and risk of bias 2.0 to assess bias.

Dupilumab demonstrated a cumulative probability ranking of 96.0% for SCORAD improvement. It was found to be more effective than melatonin, probiotics, SCG, synbiotic, and vitamin D. For EASI scores, pimecrolimus, dupilumab, and nemolizumab were superior to probiotics. Pimecrolimus showed a cumulative probability ranking of 99.9%.

The authors note that adverse events, serious adverse events, discontinuations, and tolerability were not reported. The practice relevance suggests these treatments show potential as favorable options for managing pediatric atopic dermatitis. The study does not establish causation for all associations and relies on data from the included network meta-analysis.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedMay 2026
View Original Abstract ↓
Atopic Dermatitis (AD) in children is a common chronic skin condition characterized by dry, itchy and inflamed skin. Various treatments have been applied in the management of AD in children, but the differences in efficacy of different treatment options have not been systematically summarized. The aim of this study was to compare the efficacy of different treatments for atopic dermatitis in children by network meta-analysis. We conducted a systematic literature search to select randomized controlled trials (RCTs) that met the inclusion criteria. Databases included PubMed, EMBASE, Cochrane Library, and Web of Science, with a March 10, 2025, search deadline. Certainty of evidence was graded using the CINeMA tool, and risk of bias was assessed using risk of bias 2.0. The efficacy of different treatment regimens was compared using Bayesian network meta-analysis with R software. The primary outcome indicators were the SCORAD (Clinical Score for Atopic Dermatitis) and EASI (Atopic Dermatitis Area and Severity Index) scores. Thirty-two randomized controlled trials (n=3961) were included. Meta-analysis showed Dupilumab was more effective than Melatonin, Probiotics, SCG, Synbiotic, and Vitamin D for SCORAD. Cumulative probability rankings indicated Dupilumab (96.0%), Tralokinumab (86.8%), and PEC (69.2%) as the top treatments. For EASI, Pimecrolimus, Dupilumab, and Nemolizumab were superior to Probiotics, with Pimecrolimus showing the highest efficacy (99.9%). Dupilumab may offer greater benefits in reducing SCORAD scores, while Pimecrolimus appears to be more effective for improving EASI. These treatments show potential as favorable options for managing pediatric atopic dermatitis. https://www.crd.york.ac.uk/PROSPERO/view/CRD420250650919, identifier CRD420250650919.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.